3 documents found, page 1 of 1
Single mutation on Trastuzumab modulates the stability of antibody–drug conjuga...
Ferhati, Xhenti; Jiménez-Moreno, Ester; Hoyt, Emily A.; Salluce, Giulia; Cabeza-Cabrerizo, Mar; Navo, Claudio D.; Compañón, Ismael; Akkapeddi, PadmaAntibody-drug conjugates (ADCs) are a class of targeted therapeutics used to selectively kill cancer cells. It is important that they remain intact in the bloodstream and release their payload in the target cancer cell for maximum efficacy and minimum toxicity. The development of effective ADCs requires the study of factors that can alter the stability of these therapeutics at the atomic level. Here, we present...
IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: an update
Oliveira, Mariana L.; Akkapeddi, Padma; Ribeiro, Daniel; Melão, Alice; Barata, João T.Interleukin 7 (IL-7) and its receptor (IL-7R, a heterodimer of IL-7Rα and γc) are essential for normal lymphoid development. In their absence, severe combined immunodeficiency occurs. By contrast, excessive IL-7/IL-7R-mediated signaling can drive lymphoid leukemia development, disease acceleration and resistance to chemotherapy. IL-7 and IL-7R activate three main pathways: STAT5, PI3K/Akt/mTOR and MEK/Erk, ulti...
Antibody based therapy for T-cell acute lymphoblastic leukemia : targeting IL-7...
Akkapeddi, PadmaA Leucemia Linfoblástica Aguda de células T (LLA-T) é um cancro hematológico agressivo, para o qual a abordagem terapêutica atual consiste em regimes intensivos de quimioterapia multiagente, frequentemente levando a efeitos secundários a longo prazo que afetam a qualidade de vida dos doentes. Apesar do sucesso terapêutico em casos pediátricos, as recidivas ainda ocorrem em 10-20% dos casos, e o prognóstico é co...